Historical Valuation
Karyopharm Therapeutics Inc (KPTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.86 is considered Undervalued compared with the five-year average of -2.17. The fair price of Karyopharm Therapeutics Inc (KPTI) is between 523.78 to 553.54 according to relative valuation methord. Compared to the current price of 8.34 USD , Karyopharm Therapeutics Inc is Undervalued By 98.41%.
Relative Value
Fair Zone
523.78-553.54
Current Price：8.34
98.41%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Karyopharm Therapeutics Inc (KPTI) has a current Price-to-Book (P/B) ratio of -0.23. Compared to its 3-year average P/B ratio of -2.96 , the current P/B ratio is approximately -92.14% higher. Relative to its 5-year average P/B ratio of -3.42, the current P/B ratio is about -93.20% higher. Karyopharm Therapeutics Inc (KPTI) has a Forward Free Cash Flow (FCF) yield of approximately -72.84%. Compared to its 3-year average FCF yield of -122.24%, the current FCF yield is approximately -40.41% lower. Relative to its 5-year average FCF yield of -83.15% , the current FCF yield is about -12.40% lower.
P/B
Median3y
-2.96
Median5y
-3.42
FCF Yield
Median3y
-122.24
Median5y
-83.15
Competitors Valuation Multiple
AI Analysis for KPTI
The average P/S ratio for KPTI competitors is 235.25, providing a benchmark for relative valuation. Karyopharm Therapeutics Inc Corp (KPTI.O) exhibits a P/S ratio of 0.86, which is -99.63% above the industry average. Given its robust revenue growth of 13.57%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for KPTI
1Y
3Y
5Y
Market capitalization of KPTI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KPTI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KPTI currently overvalued or undervalued?
Karyopharm Therapeutics Inc (KPTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.86 is considered Undervalued compared with the five-year average of -2.17. The fair price of Karyopharm Therapeutics Inc (KPTI) is between 523.78 to 553.54 according to relative valuation methord. Compared to the current price of 8.34 USD , Karyopharm Therapeutics Inc is Undervalued By 98.41% .
What is Karyopharm Therapeutics Inc (KPTI) fair value?
KPTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Karyopharm Therapeutics Inc (KPTI) is between 523.78 to 553.54 according to relative valuation methord.
How does KPTI's valuation metrics compare to the industry average?
The average P/S ratio for KPTI's competitors is 235.25, providing a benchmark for relative valuation. Karyopharm Therapeutics Inc Corp (KPTI) exhibits a P/S ratio of 0.86, which is -99.63% above the industry average. Given its robust revenue growth of 13.57%, this premium appears unsustainable.
What is the current P/B ratio for Karyopharm Therapeutics Inc (KPTI) as of Jan 10 2026?
As of Jan 10 2026, Karyopharm Therapeutics Inc (KPTI) has a P/B ratio of -0.23. This indicates that the market values KPTI at -0.23 times its book value.
What is the current FCF Yield for Karyopharm Therapeutics Inc (KPTI) as of Jan 10 2026?
As of Jan 10 2026, Karyopharm Therapeutics Inc (KPTI) has a FCF Yield of -72.84%. This means that for every dollar of Karyopharm Therapeutics Inc’s market capitalization, the company generates -72.84 cents in free cash flow.
What is the current Forward P/E ratio for Karyopharm Therapeutics Inc (KPTI) as of Jan 10 2026?
As of Jan 10 2026, Karyopharm Therapeutics Inc (KPTI) has a Forward P/E ratio of -1.00. This means the market is willing to pay $-1.00 for every dollar of Karyopharm Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Karyopharm Therapeutics Inc (KPTI) as of Jan 10 2026?
As of Jan 10 2026, Karyopharm Therapeutics Inc (KPTI) has a Forward P/S ratio of 0.86. This means the market is valuing KPTI at $0.86 for every dollar of expected revenue over the next 12 months.